Alkermes plc (ALKS) Stock Forecast

NASDAQ: ALKSAnalyst ratings, price target and estimates.

ALKS analyst forecast

as of October 18, 2026
Analyst consensus
Buy
4.26 / 5 from 19 analysts
Price target
$56.21
average of analyst targets
Upside to target
+36.4%
from the latest close
Next earnings
October 27, 2026
EPS estimate $-0.08
52-week range
$27.20 – $55.22

ALKS analyst ratings

19 analysts
Strong buy
1158%
Buy
316%
Hold
421%
Sell
15%
Strong sell
00%

Number of analysts at each rating.

ALKS price target

Price $41.22Target $56.21
52-week low $27.2052-week high $55.22

The average of analyst 12-month price targets compared with the latest close and the 52-week range.

ALKS earnings per share estimates

Alkermes plc EPS estimates
PeriodAverageLowHighYear agoGrowthAnalysts
Current quarter (Sep '26)$0.25−$0.04$0.51$0.65−62.1%4
Current fiscal year (2026)$1.27$0.24$2.25$2.10−39.2%4
Next fiscal year (2027)$1.81$0.71$2.43$1.27+41.8%4

Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.

ALKS revenue estimates

Alkermes plc revenue estimates
PeriodAverageLowHighGrowthAnalysts
Current quarter (Sep '26)$465.2M$445.0M$491.1M+18.0%18
Current fiscal year (2026)$1.82B$1.79B$1.86B+23.6%19
Next fiscal year (2027)$1.94B$1.76B$2.20B+6.6%19

ALKS EPS: reported and forecast

Reported EPSEstimate (average; low–high)

Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.

ALKS revenue: reported and forecast

Reported revenueEstimate (average; low–high)

ALKS EPS estimate revisions

Alkermes plc EPS estimate revisions
Period90 days ago60 days ago30 days ago7 days agoNowChange (90 d)Revisions (30 d)
Current quarter (Sep '26)$0.36$0.42$0.25$0.25$0.25−31.6%0 up · 1 down
Current fiscal year (2026)$0.98$1.23$1.27$1.27$1.27+29.6%1 up · 1 down
Next fiscal year (2027)$1.56$1.64$1.83$1.83$1.81+16.2%0 up · 1 down

How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.

ALKS earnings surprises

Reported EPSEstimate

Reported EPS vs the consensus estimate for the last 12 quarters; ALKS beat in 8 of 12.

What analysts expect from ALKS

19 analysts cover Alkermes; their consensus rating is buy (4.26 on a 1–5 scale, where 5 is a strong buy). The average price target is $56.21, 36.4% above the latest close of $41.22. Analysts expect earnings of $1.27 per share for 2026, −39.2% from a year earlier. For 2027 the average estimate is $1.81 per share on revenue of $1.9 billion. Alkermes beat the EPS estimate in 8 of the last 12 quarters.

Related: ALKS income statement, ALKS key metrics, ALKS chart. See the ALKS stock overview for the latest quote and news.

ALKS forecast FAQ

What is Alkermes's price target?

The average analyst price target for Alkermes is $56.21, 36.4% above the latest close of $41.22.

Is Alkermes a buy, hold or sell?

Of 19 analysts covering Alkermes, 11 rate it a strong buy, 3 a buy, 4 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.

What is Alkermes's EPS forecast?

Analysts forecast $1.27 per share for 2026 (range $0.24 to $2.25); for 2027 the estimate is $1.81.

What is Alkermes's revenue forecast?

The average revenue estimate for 2026 is $1.8 billion, growth of 23.6%; for 2027 it is $1.9 billion.

When does Alkermes report earnings?

Alkermes is expected to report results for the quarter ending September 30, 2026 on October 27, 2026; the EPS estimate is $-0.08.

Does Alkermes usually beat earnings estimates?

Alkermes reported EPS at or above the analyst estimate in 8 of the last 12 quarters.

Drug Manufacturers - Specialty & Generic: forecast